Is Agios Pharmaceuticals, Inc. (AGIO) Overvalued?
We dive into why Agios Pharmaceuticals, Inc. (AGIO) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Agios Pharmaceuticals, Inc.’s (AGIO) Stock Is Down 9.03%
As of Thursday, July 30, Agios Pharmaceuticals, Inc.’s AGIO share price has dipped by 9.03%, which has investors questioning if this is right time to buy.Michael Rose
What You Need to Know About Agios Pharmaceuticals, Inc.'s Q3 Earnings
Agios Pharmaceuticals, Inc.'s fiscal Q3 earnings report was released on Thursday, July 30. Let's dive in to see if (AGIO) missed or beat analyst's expectations.Michael Rose
Why Agios Pharmaceuticals, Inc.’s (AGIO) Stock Is Down 7.34%
As of Tuesday, July 21, Agios Pharmaceuticals, Inc.’s AGIO share price has dipped by 7.34%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Agios Pharmaceuticals, Inc.’s (AGIO) Stock Is Up 15.94%
As of Tuesday, July 07, Agios Pharmaceuticals, Inc.’s AGIO share price has surged by 15.94%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | AGIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,007.8 | $286.3 | 53% |
|
| Shares Out (Mil) | 59.5 | 54.2 | 51% |
|
| Institutional Ownership | 98.8% | 92.8% | 82% |
|
| Float (Mil) | 50.0 | 39.7 | 47% |
|
| Beta | 0.54 | 0.94 | 31% |
|
| Avg Daily Volume (000s) | 1,123 | 534 | 72% |
|
| Price Change (52-week) |
(7.2%) | 58.7% | 38% |
|
| Growth | AGIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (4.7%) | (10.1%) | 34% |
|
| EPS (5yr) | (8.5%) | 16.0% | 22 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (20.0%) | (15.6%) | 33% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 7 | |
| Current EPS | ($1.190) | ($5.634) | ($3.947) | |
| Month Ago EPS | ($1.479) | ($6.203) | ($4.588) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($1.431) | ($5.970) | ($4.603) | |
| Year/Year Chg | (29.7%) | (20.9%) | (71.0%) | |
| Financials | AGIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $98 | $37 | 26% |
|
| Net Income (TTM) (Mil) | ($411) | ($43) | 3% |
|
| EPS (TTM) | ($7.008) | ($1.400) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($361) | ($31) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $19 | $2 | 62% |
|
| Long-Term Debt (Q1) (Mil) | $12 | $4 | 29% |
|
| Enterprise Value (Q1) (Mil) | $859 | $160 | 39% |
|
| Valuation | AGIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.95 | 2.77 | 49% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | AGIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (270.8%) | 64.2% | 1% |
|
| Net Margin | (418.2%) | (75.9%) | 2% |
|
| ROA | (31.9%) | (47.3%) | 16% |
|
| ROE | (34.3%) | (55.0%) | 19% |
|
| Liabilities to Assets | 7.4% | 29.6% | 4% |
|
| F-Score | 4 | 2 | 34% |
|
Agios Pharmaceuticals, Inc. did not pass any screens on 8/20/2026.
